Trial reportJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2009
Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas.
Trial report in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 112 citations in OpenAlex.
- Phase II trial of S-1 treatment as palliative-intent chemotherapy for previously treated advanced thymic carcinoma.Cancer medicine · 2020Trial
- Precision Oncology in Thymic Epithelial Tumors: Therapeutic Horizons and Implementation Barriers.International journal of molecular sciences · 2026Review
- Oncologic strategies and options for the management of metastatic thymic carcinoma.Mediastinum (Hong Kong, China) · 2026Review
- Rapid Response to Lenvatinib and Disease Flare After Discontinuation in a Patient With Thymic Carcinoma Harboring KIT Exon 11 Mutation: A Case Report.JTO clinical and research reports · 2024Article
- Review
- Narrative review of indication and management of induction therapy for thymic epithelial tumors.Mediastinum (Hong Kong, China) · 2024Review
- Autoimmunity in thymic epithelial tumors: a not yet clarified pathologic paradigm associated with several unmet clinical needs.Frontiers in immunology · 2024Review
- Review
- Review
- Immunotherapy and Targeted Therapies Efficacy in Thymic Epithelial Tumors: A Systematic Review.Biomedicines · 2023Review
- Emerging therapies in thymic epithelial tumors (Review).Oncology letters · 2023Review
- Thymic Epithelial Tumors: An Evolving Field.Life (Basel, Switzerland) · 2023Review
- Phosphoproteomic Analysis Identifies TYRO3 as a Mediator of Sunitinib Resistance in Metastatic Thymomas.Cancers · 2022Article
- Review
- Thymic tumours: a single center surgical experience and literature review on the current diagnosis and management of thymic malignancies.Gland surgery · 2021Review
- Review
- GOECP/SEOR radiotherapy guidelines for thymic epithelial tumours.World journal of clinical oncology · 2021Review
- An Overview on Molecular Characterization of Thymic Tumors: Old and New Targets for Clinical Advances.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Systemic treatments for thymic tumors: a narrative review.Mediastinum (Hong Kong, China) · 2021Review
- An overview: ongoing systemic therapy trials in thymic epithelial tumors around the world-will anything "hit"?Mediastinum (Hong Kong, China) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Thymic malignancies are rare tumors of the mediastinum. c-KIT is highly expressed in thymic carcinomas (TC) but infrequently in thymomas. Anecdotal experience suggests activity of imatinib mesylate in TC. Patients with unresectable World Health Organization B3 thymomas or TC, performance status 0 to 2, good organ function, and measurable disease were enrolled in this study. Imatinib was administered at 600 mg PO daily. Seven patients were recruited at one institution: two World Health Organization B3 thymomas and five TC. Imatinib treatment was generally well tolerated. Two patients had stable disease and five progressed. Median survival was 4 months, and median time to progression was 2 months. c-KIT expression was found in one of four samples by immunohistochemistry. No mutations were detected in the c-KIT or PDGFRA genes in three samples analyzed. Imatinib has no major activity in this rare tumor. Given the small number of patients treated in this study, selection based on presence of c-KIT mutations might be warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.